27.07.2026
Fluoselect
Oncology
2 cancer types
Trastuzumab: binding selectivity in a 2-tissue co-culture
About the drug
Trastuzumab (Herceptin) is a monoclonal antibody used to treat breast cancer and stomach cancer. It was the first targeted therapy to treat HER2-expressing cancers and it increases the overall survival of breast cancer patients by almost 40%. The high selectivity of Trastuzumab limits therapeutic indications to cancers expressing the HER2 receptor.
Specific binding of Trastuzumab-FITC to HER2-high breast cancer spheroids (SK-BR3) and no binding to HER2-negative breast cancer spheroids (Figure 2-3)Half of the maximal binding to HER2-high breast cancer spheroids after 85 minutes.
Works with the tools and workflows you already use.
Ready-to-run microtissues for consistent material.
Built on the same core technology that expands into multi-tissue systems.
Specific binding of Trastuzumab-FITC to HER2-high breast cancer spheroids (SK-BR3) and no binding to HER2-negative breast cancer spheroids (Figure 2-3)
Half of the maximal binding to HER2-high breast cancer spheroids after 85 minutes.
References
Clifford A, Hudis MD. Trastuzumab – Mechanism of Action and Use in Clinical Practice. New England Journal of Medicine, 357:39-51 (2007).
Dai X, Cheng H, Bai Z, Li J. Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping. Journal of Cancer, 8(16): 3131-3141 (2017).
Future of Discovery
Predictive biology
starts today